Psychedelic Therapies Gain Global Medical Attention

Global mental health research is entering a new phase as psychedelic-assisted treatments for severe depression, PTSD, addiction, and treatment-resistant mental illness gain increasing scientific attention, with international policy shifts accelerating studies into compounds such as psilocybin, MDMA, LSD, and ibogaine. Researchers say these therapies are showing promising results in helping patients who do not respond to conventional psychiatric treatments, particularly in reducing trauma symptoms and severe depression when used under strict medical supervision. While the early findings are encouraging, healthcare professionals stress the importance of rigorous clinical trials, ethical regulation, and patient safety to ensure these treatments are used responsibly and effectively. As mental health challenges continue to rise globally, including in South Africa, these emerging therapies may offer new hope for more personalised and effective approaches to psychiatric care in the future.